Drawing for REPLIMUNE

USPTO serial 87322937

REPLIMUNE

Reviewed by CopyMark Law Group

Reg. 5353768Status 705Renewal
Filing date
Status date
Registration date
Dec 12, 2017
Examiner
JOHNSON, CLINTON J
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 705: Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights.

Need help with REPLIMUNE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Melanie Howard

Melanie Howard LOEB & LOEB LLP10100 Santa Monica Boulevard, Suite 2200LOS ANGELES, CA 90067United States

Goods and services

ClassDescriptionStatusFirst use
005Biological preparations in the nature of viruses for the treatment of cancer, tumors, [ infectious, ] oncological, [ autoimmune, and immune system ] diseases and disorders; viruses for the treatment of cancer and tumors; viruses for inducing immune response for the treatment of cancer, tumors, [ infectious, ] oncological, [ autoimmune, and immune system ] diseases and disorders; pharmaceutical preparations and pharmaceutical substances for the treatment of [ infectious, ]oncological, [ autoimmune, and immune system ] diseases and disorders; pharmaceutical preparations and pharmaceutical substances used for the prevention and treatment of cancer and tumors; pharmaceuticals, namely, [ anti-infectives ] for the treatment of cancer, tumors, [ infectious, ] oncological, [ autoimmune, and immune system ] diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceuticals for inducing immune response for the treatment of cancer and tumors; vaccines; immunotherapy products, namely, pharmaceuticals for the treatment of cancer, tumors, [ infectious, ] oncological [ , autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system ] diseases and disordersACTIVE—
042[ Pharmaceutical drug research and development services; research and development of vaccines and medicines; information, advisory and consultancy services regarding research and development in the fields of pharmaceuticals, vaccines and medicines ]SECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 26, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Aug 26, 2024C15PREGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Jun 12, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 6, 2023E815TEAS SECTION 8 & 15 RECEIVED—
Dec 12, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 4, 2020COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Sep 20, 2018COC.CORRECTION UNDER SECTION 7 - PROCESSED—
Sep 10, 2018EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
Apr 11, 2018PRAMPOST REGISTRATION ACTION MAILED - SEC. 7—
Mar 28, 2018APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Feb 20, 2018ES7RTEAS SECTION 7 REQUEST RECEIVED—
Dec 12, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 26, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 26, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 6, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 19, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 18, 2017AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Aug 14, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Aug 14, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 14, 2017ALIEASSIGNED TO LIE—
Aug 4, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 4, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 19, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 11, 2017TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 4, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 4, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 4, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 27, 2017DOCKASSIGNED TO EXAMINER—
Feb 7, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 6, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance